Initial experience with stereotactic body radiation therapy for localized prostate cancer using helical tomotherapy

Clinical and Translational Oncology

Volumn 16, Issue 4, 2014, Pages 380-385

  Macias, V A ^a   Blanco, M L ^a   Perez Romasanta, L A ^a  

^a HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

Author keywords

Dose escalation; Hypofractionated radiotherapy; Prostate cancer; Stereotactic body radiation therapy (SBRT)

Indexed keywords

ABDOMINAL PAIN; ACUTE TOXICITY; AGED; ARTICLE; BLADDER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SIZE; CLINICAL ARTICLE; DIARRHEA; DOSIMETRY; DYSURIA; FEMUR; GASTROINTESTINAL TOXICITY; HIGH RISK PATIENT; HUMAN; LOW RISK POPULATION; MALE; MEGAVOLTAGE RADIOTHERAPY; NOCTURIA; PATIENT; PENIS; PROSPECTIVE STUDY; PROSTATE; PROSTATE CANCER; RADIATION DOSE; RADIATION DOSE DISTRIBUTION; RADIATION DOSE FRACTIONATION; RECTUM; SEMINAL VESICLE; STEREOTACTIC BODY RADIATION THERAPY; TARGET ORGAN; TOMOTHERAPY; URINARY FREQUENCY; URINARY URGENCY; UROGENITAL TRACT INJURY; CLINICAL TRIAL; INTENSITY MODULATED RADIATION THERAPY; MIDDLE AGED; PROSTATIC NEOPLASMS; RADIOSURGERY; RISK FACTOR;

AGED; HUMANS; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; RADIOSURGERY; RADIOTHERAPY, INTENSITY-MODULATED; RISK FACTORS;

EID: 84898596318     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: 10.1007/s12094-013-1089-y     Document Type: Article

References (30)

1. Brenner DJ, Hall EJ. Fractionation and protraction for radiotherapy of prostate carcinoma. Int J Radiat Oncol Biol Phys. 1999;43(5):1095-101. (Pubitemid 29144800)
2. Fowler JF, Ritter MA, Chappell RJ, Brenner DJ. What hypofractionated protocols should be tested for prostate cancer? Int J Radiat Oncol Biol Phys. 2003;56(4):1093-104. (Pubitemid 36794043)
3. Yeoh EE, Holloway RH, Fraser RJ, Botten RJ, Di Matteo AC, Butters J, et al. Hypofractionated versus conventionally fractionated radiation therapy for prostate carcinoma: updated results of a phase III randomized trial. Int J Radiat Oncol Biol Phys. 2006;66(4):1072-83. (Pubitemid 44633501)
4. Lukka H, Hayter C, Julian JA, Warde P, Morris WJ, Gospodarowicz M, et al. Randomized trial comparing two fractionation schedules for patients with localized prostate cancer. J Clin Oncol. 2005;23(25):6132-8.
5. Pollack A. Five year results of a randomized external beam radiotherapy hypofractionation trial for prostate cancer. In: International Journal of Radiation Oncology Biology and Physics. http://www.redjournal.org/article/S0360- 3016(11)00824-8/fulltext. Accessed 04 Apr 2013.
6. Arcangeli G, Saracino B, Gomellini S, Petrongari MG, Arcangeli S, Sentinelli S, et al. A prospective phase III randomized trial of hypofractionation versus conventional fractionation in patients with high-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2010;78(1):11-8.
7. Dearnaley D, Syndikus I, Sumo G, Bidmead M, Bloomfield D, Clark C, et al. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial. Lancet Oncol. 2012;13(1):43-54.
8. Macías V, Biete A. Hypofractionated radiotherapy for localised prostate cancer. Review of clinical trials. Clin Transl Oncol. 2009;11(7):437-45.
9. King CR, Brooks JD, Gill H, Pawlicki T, Cotrutz C, Presti JC. Stereotactic body radiotherapy for localized prostate cancer: interim results of a prospective phase II clinical trial. Int J Radiat Oncol Biol Phys. 2009;73(4):1043-8.
10. King CR, Brooks JD, Gill H, Presti JC Jr. Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2012;82(2):877-82.
11. Friedland JL, Freeman DE, Masterson-McGary ME, Spellberg DM. Stereotactic body radiotherapy: an emerging treatment approach for localized prostate cancer. Technol Cancer Res Treat. 2009;8(5):387-92.
12. McBride SM, Wong DS, Dombrowski JJ, Harkins B, Tapella P, Hanscom HN, et al. Hypofractionated stereotactic body radiotherapy in low-risk prostate adenocarcinoma: preliminary results of a multi-institutional phase 1 feasibility trial. Cancer. 2012;118(15):3681-90.
13. Chen LN, Suy S, Uhm S, Oermann EK, Ju AW, Chen V, et al. Stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer: the Georgetown University experience. Radiat Oncol. 2013;8(1):58.
14. Bentzen SM, Constine LS, Deasy JO, Eisbruch A, Jackson A, Marks LB, et al. Quantitative analyses of normal tissue effects in the clinic (QUANTEC): an introduction to the scientific issues. Int J Radiat Oncol Biol Phys. 2010;76(3 Suppl):S3-9.
15. Study Number 0415. In: RTOG. Clinical trials. http://www.rtog.org/ ClinicalTrials/ProtocolTable/StudyDetails.aspx?study=0415. Accessed 04 Apr 2013.
16. Gulliford SL, Foo K, Morgan RC, Aird EG, Bidmead AM, Critchley H, et al. Dose-volume constraints to reduce rectal side effects from prostate radiotherapy: evidence from MRC RT01 Trial ISRCTN 47772397. Int J Radiat Oncol Biol Phys. 2010;76(3):747-54.
17. Katz A, Freeman D, Aronovitz J, Fuller D, Bolzicco G, Meier R, et al. Five-year biochemical control rates for stereotactic body radiation therapy for organ-confined prostate cancer: a multi-institutional pooled analysis. Int J Radiat Oncol Biol Phys. 2012;84(3):S147-8.
18. Katz A. Stereotactic body radiation therapy offers a safe, non-invasive treatment for prostate cancer patients over 70 years old. Int J Radiat Oncol Biol Phys. 2012;84(3):S361.
19. Mantz CA, Fernandez E. Real-time target tracking prostate SBRT: quality of life and disease outcomes from a phase II trial. Int J Radiat Oncol Biol Phys. 2012;84(3):S368.
20. Kim CH, Beriwal S, Benoit RM, Houser C, Smith RP. Is there a secondary spike in urinary symptoms with Cs131 prostate brachytherapy? A longitudinal analysis with patient reported epic survey and AUA score. Int J Radiat Oncol Biol Phys. 2012;84(3):S416-7.
21. Katz A, Ferrer M, Suárez JF. Comparison of quality of life after stereotactic body radiotherapy and surgery for early-stage prostate cancer. Radiat Oncol. 2012;7:194.
22. Katz AJ, Santoro M, Ashley R, Diblasio F, Witten M. Stereotactic body radiotherapy for organ-confined prostate cancer. BMC Urol. 2010;10:1.
23. Mak RH, Hunt D, Shipley WU, Jones CU, Lukka HR, Bahary JP, et al. Acute and late urinary toxicity after radiation therapy in men with and without an intact prostate gland: a secondary analysis of RTOG 9408 and 9601 suggesting this toxicity is not due to bladder injury. Int J Radiat Oncol Biol Phys. 2012;84(3):S14.
24. Macias V, Gonzalez Celador R, Marti-Macia C, Cigarral C, Perez-Romasanta LA. Prognostic factors for acute toxicity in prostate cancer patients treated with high-dose hypofractionated radiotherapy. Clin Transl Oncol. 2013;86(4):709-15.
25. Zelefsky MJ, Yamada Y, Fuks Z, Zhang Z, Hunt M, Cahlon O, et al. Long-term results of conformal radiotherapy for prostate cancer: impact of dose escalation on biochemical tumor control and distant metastases-free survival outcomes. Int J Radiat Oncol Biol Phys. 2008;71(4):1028-33.
26. Kupelian PA, Willoughby TR, Reddy CA, Klein EA, Mahadevan A. Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Cleveland Clinic experience. Int J Radiat Oncol Biol Phys. 2007;68(5):1424-30. (Pubitemid 47176809)
27. Madsen BL, Hsi RA, Pham HT, Fowler JF, Esagui L, Corman J. Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5 Gy in five fractions for localized disease: first clinical trial results. Int J Radiat Oncol Biol Phys. 2007;67(4):1099-105.
28. Boike TP, Lotan Y, Cho LC, Brindle J, DeRose P, Xie X-J, et al. Phase I dose-escalation study of stereotactic body radiation therapy for low- and intermediate-risk prostate cancer. J Clin Oncol. 2011;29(15):2020-6.
29. Tang CI, Loblaw DA, Cheung P, Holden L, Morton G, Basran PS, et al. Phase I/II study of a five-fraction hypofractionated accelerated radiotherapy treatment for low-risk localised prostate cancer: early results of pHART3. Clin Oncol (R Coll Radiol). 2008;20(10):729-37.
30. Menkarios C, Vigneault É, Brochet N, Nguyen DHA, Bahary J-P, Jolicoeur M, et al. Toxicity report of once weekly radiation therapy for low-risk prostate adenocarcinoma: preliminary results of a phase I/II trial. Radiat Oncol. 2011;6:112.